Your browser doesn't support javascript.
loading
Antiretroviral therapy reduces but does not normalize immune and vascular inflammatory markers in adults with chronic HIV infection in Kenya.
Temu, Tecla M; Zifodya, Jerry S; Polyak, Stephen J; Wagoner, Jessica; Wanjalla, Celestine N; Masyuko, Sarah; Nyabiage, Jerusha; Kinuthia, John; Bloomfield, Gerald S; Page, Stephanie T; Farquhar, Carey.
Afiliação
  • Temu TM; Department of Global Health, University of Washington, Seattle, Washington.
  • Zifodya JS; Department of Medicine, Tulane University, New Orleans, Louisiana.
  • Polyak SJ; Department of Laboratory Medicine, University of Washington, Seattle, Washington.
  • Wagoner J; Department of Laboratory Medicine, University of Washington, Seattle, Washington.
  • Wanjalla CN; Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
  • Masyuko S; Department of Global Health, University of Washington, Seattle, Washington.
  • Nyabiage J; Ministry of Health.
  • Kinuthia J; Kenyatta National Hospital, Nairobi, Kenya.
  • Bloomfield GS; Department of Global Health, University of Washington, Seattle, Washington.
  • Page ST; Kenyatta National Hospital, Nairobi, Kenya.
  • Farquhar C; Department of Medicine and Duke Global Health Institute, Duke University, Durham, North Carolina.
AIDS ; 35(1): 45-51, 2021 01 01.
Article em En | MEDLINE | ID: mdl-33055570
ABSTRACT

INTRODUCTION:

Markers of monocyte/macrophage activation and vascular inflammation are associated with HIV-related cardiovascular diseases (CVD) and mortality. We compared these markers among African people living with HIV (PLWH) and HIV-negative adults, and examined risk factors associated with elevated biomarkers (>75th percentile) in PLWH on antiretroviral therapy (ART).

DESIGN:

Cross-sectional study.

METHODS:

We measured serum concentrations of a gut integrity biomarker (intestinal-fatty acid binding protein), monocyte/macrophage activation biomarkers (soluble CD14 and CD163), and vascular inflammation biomarkers [soluble intercellular adhesion molecule 1 (sICAM-1) and soluble vascular adhesion molecule 1 (sVCAM-1)]. We assessed the relationship of these inflammatory parameters with HIV, using logistic regression adjusting for traditional CVD risk factors.

RESULTS:

Among the 541 participants, median age was 43 years and half were female. Among 275 PLWH, median CD4 T-cell count and duration of ART use was 509 cells/µl and 8 years, respectively. PLWH had significantly higher prevalence of elevated inflammatory biomarkers compared with HIV-negative individuals even after adjustment for traditional CVD risk factors. Compared with individuals without HIV, the prevalence of elevated biomarkers was highest among persons with detectable viral load and CD4 T-cell counts 200 cells/µl or less. In a subanalysis among PLWH, nadir CD4 T-cell count 200 cells/µl or less was associated with elevated soluble CD14 (sCD14); dyslipidemia with elevated sCD14, sICAM-1, and sVCAM-1; and overweight/obesity with reduced sCD14. Longer ART exposure (>4 years) was associated with reduced sVCAM-1 and sICAM-1.

CONCLUSION:

HIV and not traditional CVD risk factors is a primary contributor of monocyte/macrophage activation and inflammation despite ART. Anti-inflammatory therapies in addition to ART may be necessary to reduce these immune dysregulations and improve health outcomes of African PLWH.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Antirretrovirais Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Antirretrovirais Idioma: En Ano de publicação: 2021 Tipo de documento: Article